Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind active-controlled study of WXSH0493 versus febuxostat in primary gout with hyperuricemia
CTR20252975Phase 2Active
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd.
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WXSH0493 in gout, hyperuricemia, sponsored by Jiangsu Kanion Pharmaceutical Co., Ltd.. Started Aug 2025; status: active.
02
Drugs
WXSH0493
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on CTR20252975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252975.